DNA methylation biomarker selected by an ensemble machine learning approach

predicts frailty in an HIV-positive veteran population

Chang Shu[1,2], Amy C. Justice[2,3], Xinyu Zhang[1,2], Vincent C. Marconi[4], Dana B.

Hancock[5], Eric O. Johnson[5,6], Ke Xu[1,2]

1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06516

2. Connecticut Veteran Healthcare System, West Haven, CT, 06515

3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06516

4. Division of Infectious Disease, Emory University School of Medicine, Atlanta GA

5. Center for Omics Discovery and Epidemiology, Behavioral Health Research Division,

RTI International, Research Triangle Park, NC, USA

6. Fellow Program, RTI International, Research Triangle Park, NC, USA.

All corresponding address to

Ke Xu, M.D., Ph.D.

Associate Professor of Psychiatry

Yale School of Medicine

Email: ke.xu@yale.edu

Tel: 203-932-5711x7430

Word count: 2966

Abstract: 332

Figures: 7

Tables: 3

Abstract

Background: With the improved life expectancy in people living with HIV, predicting

individual frailty is important for clinical care. DNA methylation (DNAm) has been

previously linked to aging and mortality in non-HIV populations. We aim to establish a

panel of DNAm biomarkers to predict frailty in HIV-positive population.

Methods: Our samples consist of HIV-positive participants (N_{total}=1,081) from the

Veterans Aging Cohort Study (VACS) and were divided into the training set

($N_{training}$=460), the validation set ($N_{validation}$=114), and the testing set ($N_{testing}$=507). We

used a well-established score, VACS Index, as a measure of frailty. Model training and

fine-tuning were conducted using the ensemble method that aggregated prediction

results of four base models. The final number of features were determined in the

validation set and the model performance was assessed in the testing set. We

conducted a survival analysis to assess whether the predicted frailty was associated

with 10-year mortality and gene ontology enrichment analysis of the predictive CpG

sites was performed.

Results: We selected a panel of 393 CpGs to build the ensemble machine learning

model. The prediction model showed an excellent performance on predicting frailty with

Area Under Curve of 0.809 (95%CI: 0.767-0.851) and balanced accuracy of 0.653 in the

testing set. The predicted frailty based on our model was significantly associated with

10-year mortality (hazard ratio=1.79, p=4E-05). These 393 CpGs were located within or

near 280 genes that were enriched in biological pathways including immune and

inflammation response.

46   **Conclusions:** We identified a panel of predictive DNAm features associated with frailty

47   and mortality among HIV-positive population. These DNAm features may serve as

48   biomarkers to predict frailty people who live with HIV.

50   **Keywords:** DNA methylation, HIV, frailty, mortality, machine learning prediction

Introduction

Combination antiretroviral therapy has significantly improved life expectancy among HIV-positive individuals. The prolonged life expectancy increases frailty risk in the HIV population. The prevalence of frailty in people living with HIV is significantly higher and onset of frailty occurs at an earlier age compared to the general population (1). Frailty is characterized by marked vulnerability and is associated with increased mortality. Thus, prediction of frailty is important to identify vulnerable group and deliver clinical care to highly vulnerable HIV-positive patients. At present, frailty is usually defined by clinical symptoms (e.g., Fried's frailty phenotype, Rockwood and Mitnitski's Frailty Index) or a combination of lab tests that indicate organ damage such as the Veterans Aging Cohort Study index (VACS index) (2). No biomarkers available to capture the early stage of the frailty to predict individual vulnerability in HIV-positive patients.

A large body of evidence has demonstrated that epigenetic modification adapts internal and external environmental changes and that is associated with early stage of pathophysiological processes (3-6). DNAm, one type of the most widely studied epigenetic marks, is strongly related with aging (7-9), substance use (e.g. cigarette smoking and alcohol consumption) (10-16), and a variety of diseases (3-6, 17, 18). Because DNAm is relatively stable and easy to detect from body fluids biospecimen through non-invasive procedure, DNAm marks have emerged as robust biomarkers for cancer diagnosis (19), disease subtype classification (20, 21) and treatment response monitoring (22, 23).

DNAm may play an important role in frailty among HIV-positive individuals. Frailty

is associated with elevated inflammation markers such as IL-6 and hsCRP in HIV-

positive individuals (24). Genes involved in immune and inflammation processes are

also subject to epigenetic modification in immune cells. We previously reported

association of two CpG sites in the promoter region of *NLRC5* with HIV infection (25),

and *NLRC5* is a major transcriptional activator of MHC class I gene. DNAm was also

linked to HIV comorbid medical diseases such as HIV-positive diabetes and kidney

function (26, 27). Furthermore, aging, a critical contributor to frailty, is significantly

associated with thousands of CpGs in the epigenome, and the epigenetic clock and

DNAm age are becoming widely recognized (7-9). DNAm age is significantly correlated

with physical frailty in HIV-negative individuals (28) and HIV-positive individuals (29). In

HIV-positive individuals, the average DNAm age is accelerated 5 to 10 years faster than

HIV-negative individuals (30-33). DNAm accelerated 10 years faster in frailty individuals

in comparing to non-frailty individuals in HIV-positive population (29). These age-related

DNAm signatures are predictive of mortality (34-39). Therefore, we hypothesize that

DNAm is associated with frailty and that DNAm signatures in blood can serve as

biomarkers to predict frailty and mortality among HIV-positive individuals.

Machine learning methods have been applied to select informative DNAm

features for clinical diagnosis and classification of complex diseases(15, 40, 41).

Ensemble machine learning method can aggregate multiple machine learning models

(base model) usually provide better prediction outcomes than single base model (42,

43). Ensemble method has been shown to perform well in personalized medicine and

disease outcomes such as cancer and diabetes (44, 45).

In this study, by applying an ensemble learning approach, we aimed to identify

DNAm features that can serve as biomarkers on frailty and to link frailty-associated

DNAm to mortality among HIV-positive individuals. Here, VACS index, a well-

established frailty score, was used as a measure of frailty in the HIV-positive

population(46-48). Findings from this study provide a set of DNAm biomarkers to predict

frailty for potential future clinic use and new insights into the epigenetic mechanism of

frailty and mortality in HIV pathology.

Methods

As an overview, our analytical approach is shown in the flowchart in **Figure 1**.

Briefly, we first applied an ensemble learning to improve machine learning results on

predicting frailty, then examined the association of the selected CpG features with

mortality by a survival analysis. Then, we conducted a gene-ontology enrichment

analysis of the predictive features. Lastly, we tested a meta-analysis of epigenome-wide

association (EWA) on frailty on the entire sample.

Study population

All samples in the sample set 1 and sample set 2 were from the VACS. The

VACS is a prospective cohort study of veterans focusing on clinical outcomes in HIV

infection (46). DNA samples were extracted from peripheral blood of 1,081 HIV-positive

men from the VACS. Samples in sample set 1 was randomly partitioned into training

set (80%, N=460) and validation set (20%, N=114), and samples in sample set 2 was

used as independent testing set (N=507). Table 1 presents demographic and clinical

information on age, race, smoking status, CD4 count, viral load, HIV medication

adherence, VACS index, and mortality in the training set, the validation set, and the

testing set. Comparing to the testing set, the training and validation sets included

slightly older individuals, more African Americans, and frailty individuals. There were no

significant differences in sex, smoking, HIV medication adherence, CD4 count, $\log_{10}$

HIV-1 viral load or 10-year mortality across three sample sets.

Frailty measurement

VACS index is a well-established measure for frailty among HIV population (46-

48). The VACS index is a composite score constructed by a sum of pre-assigned points

on age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine

transaminase (AST and ALT), creatine, estimated glomerular filtration rate (eGFR), and

viral hepatitis C infection (48). Frailty was defined as VACS index > 40 since the

predicted 3-year mortality of this group was 10% based on the previous report, (49).

Prediction models were developed by machine learning methods to predict frailty

(VACS index > 40) and non-frailty group (VACS index ≤ 40).

Genome-wide DNAm profiling and quality control

DNA samples in the sample set 1 were profiled by Infinium Human Methylation

450K BeadChip (HM450K), and DNA samples in sample set 2 were profiled by the

Infinium Human Methylation EPIC BeadChip. DNAm for the training and validation sets

were evaluated using the same quality control (QC) protocol (50) in the R package minfi

(51). In detail, CpG sites on sex chromosomes and within 10 base pairs of a single

nucleotide polymorphism were removed. The detection p-value threshold was set at 10^{-12}

for both the training and validation sets. After QC, 408,583 common CpG sites

between HM450K and EPIC arrays were used for analysis to ensure the same

coverage between two sets. Proportions of 6 cell types (CD4+ T cells, CD8+ T cells,

Natural Killer T cells, B cells, monocytes and granulocytes) were estimated using the

established method(52) for all samples in the sample set 1 and sample set 2.

Feature selection of CpG sites in the training set

We first pre-selected a panel of CpG sites associated with frailty based on EWA

on frailty in the training set. CpG sites with p<0.001 were preselected for building

predictive models. The marginal significance cutoff of p=0.001 was arbitrarily set to

ensure sufficient number of CpG sites for building a model. The variable importance of

each CpG in the preselected CpG sites was ranked by using Elastic-Net Regularized

Generalized Linear Models (GLMNET) variable importance ranking (a score between 0-

100) in *caret* based on 100 bootstraps (each bootstrap includes 70% of all samples). In

GLMNET, importance of zero means the feature is neglected in model construction.

CpG sites with zero variable importance for 80% of the bootstraps were removed from

model development. The remaining CpG sites were ranked based on the median

importance ranking among 100 bootstraps and were divided as different groups. The

CpG sites were grouped based on importance rank of CpG sites. Each CpG group was

used to build ensemble machine learning models.

Developing machine learning prediction models for frailty

1) Model development in the training set: We developed an ensemble

classification model that aggregated the prediction models from four base machine

learning models: random forest (RF), GLMNET, Support Vector Machines (SVM) and k-

Nearest Neighbors (KNN). These four different methods are selected to enlarge the

diversity of algorithms (53-56). Ten-fold cross-validation was used in the model training

process to minimize data overfitting. The four Models based on the number of CpG

groups were separately trained to predict frailty in the training set and then aggregated

with greedy ensemble method by using R package *caretEnsemble* (ver. 2.0.1) (57). The

prediction performance of each ensemble model was evaluated by using area under

receiver operating characteristic curve (auROC) and area under precision-recall curve

(auPRC).

2) Select final CpG group in the validation set: The CpG group with both highest

auROC and auPRC in the validation set was selected as the final feature group for the

ensemble model.

3) Independent evaluation in testing set: using ensemble model and final feature

group, we predicted the frailty group in the testing set and evaluated by using auROC

and balanced accuracy. Balanced accuracy is defined as the average accuracy

obtained on each class as shown in the following formula (58). Balanced accuracy was

used in this study to avoid biased accuracy due to imbalanced samples (58).

$$Balanced\ accuracy$$
$$= \frac{1}{2}\left(\frac{True\ positive}{True\ positive + False\ negative} + \frac{True\ negative}{True\ negative + False\ positive}\right)$$

Survival analysis

By using the final ensemble model we predicted each individual with frailty or

non-frailty in the entire samples. Kaplan-Meier survival curves presented 10-year follow-

up to visualize the survival differences by participants with predicted frailty or non-frailty.

Survival analysis was conducted by cox proportional hazards model on 10-year

mortality comparing frailty and non-frailty groups. We used age as time scale t, and our

model was adjusted for race, smoking, self-reported HIV medication adherence, log 10

of HIV viral load and CD4 count.

$$h(t) = h_0(t)\exp{(\beta_1\ methylation\ score\ +\ \beta_2\ race\ +\ \beta_3\ smoking}$$
$$+\ \beta_4\ HIV\ medication\ adherence\ +\ \beta_5\ \log_{10}(viral\ load) + \beta_6\ CD4\ count)$$

Biological interpretation of the predictive panel of CpG sites on frailty

194 We performed gene ontology (GO) enrichment analysis using *missMethyl* to

195 adjust a bias from differing numbers of CpG site per gene(59, 60). Genes contained at

196 least one predictive CpG site were used for GO analysis.

Epigenome-wide association analysis on frailty in all samples

Since DNA methylation of two sample sets was measured by two different

platforms, we performed EWAs on frailty in sample set 1 and sample set 2 separately

and then conducted a meta-analysis to detect epigenome-wide signals in the entire

samples. In each EWA, we used a two-step linear model approach as previously

described (50). The EWA model adjusted for confounding factors including age, race,

smoking, cell type proportions and control principle components. Meta-analysis of

sample set 1 and sample set 2 EWA was conducted using METAL(61). The weights of

effect size estimates were the inverse of the corresponding standard errors for the

meta-analysis(61). CpG sites with Bonferroni corrected p<0.05 were considered

statistically significant.

Results

Feature selection and ensemble model training for frailty

A panel of 856 CpGs with p<0.001 was pre-selected based on EWA in the

training set. We ranked these candidate predictors by median GLMNET importance

ranking among 100 bootstraps using 70% of the training sample. We excluded 178 CpG

sites that had variable importance of zero among 80% of the bootstraps. A final panel of

678 CpG sites were selected and were formed into 20 groups based on importance

ranking to determine the best performing CpG group for the ensemble model (**Figure 2**).

In the training set, we developed our base models independently for the 20

groups of CpGs using four commonly used machine learning classification models (53-

56): RF, GLMNET, SVM, and KNN. The performances of GLMNET, RF and SVM were

mostly comparable in terms of auROC and auPRC plateaued to 1 with increasing

number of CpGs in the training set (**Figure 3**, **Figure 4**). The performance of KNN was

not as good as the other three methods, but its auROC and auPRC remained above 0.9

in the training set. Thus, an ensemble model combined the prediction results of all four

base models was used to address imbalance performances from 4 models (**Figure 3**,

Figure 4).

In the validation set, the performances of four base models varied. Three models

of GLMNET, RF, and SVM showed good performance with both auROC and auPRC

greater than 0.8, but the performance of KNN was poor with auROC or auPRC less

than 0.8 (**Figure 3**, **Figure 4**). The ensemble model showed the best performance at

393 CpG sites with excellent performance of auROC (0.829) and auPRC (0.830). The

accuracy of this prediction model was 0.807, and the balanced accuracy that took into

account of class imbalance between frailty and non-frailty participants was 0.782. Thus,

the ensemble model with 393 features was determined as the final prediction model

(**Table S1**).

In the testing set, the ensemble model with 393 features showed excellent

performance with auROC of 0.809 (95%CI: 0.767-0.851), prediction accuracy of 0.761

and balanced accuracy of 0.653 (**Figure 5**), suggesting that an ensemble model of a

panel of 393 features enable to predict frailty.

Survival analysis

By using the ensemble model to predict participants with frailty and non-frailty

groups, we found that 10-year Kaplan-Meier curves differed between frailty and non-

frailty participants (**Figure 6**). The Kaplan-Meier curves showed that participants with

frailty showed significantly lower 10-year survival probability compared with non-frailty

participants. Using Cox proportional-hazards model to control for sex, baseline age,

race, viral load, CD4 count and antiviral medication adherence, this difference remained

significant with a hazard ratio (HR) of 1.79 (95%CI: 1.35-2.37, p=4E-05).

Biological interpretations of predictive CpGs by gene ontology enrichment

analysis

The 393 predictive CpGs were located in or near 280 genes. The top 8 enriched

pathways based these 280 genes included response to virus (p= 4.26E-05), defense

response (p=1.29E-04), cytokine receptor binding (p=1.48E-04) and regulation of

response to interferon-gamma (p= 4.15E-04) (**Figure 7, Table 2**). Our findings

suggested that the selected 393 CpG sites are biologically relevant to HIV pathogenesis

and progression.

Epigenome-wide association (EWA) on frailty

Meta-analysis on EWA of sample set 1 and sample set 2 identified 208

epigenome-wide significant CpGs after Bonferroni correction. These significant CpG

sites were located in the 112 genes and included gene previously reported association

with HIV pathogenesis. For example, cg07839457 in *NLRC5* had been previously

reported to be associated with HIV infection(25). Interestingly, 30 of 208 CpG sites were

also in the panel of machine-learning predictive CpGs (**Table 3**). Some of the

overlapped CpGs were located in viral response genes such as *IFITM1* and *PARP9*.

Discussion

In this study, we present evidences that DNAm marks in blood are predictive of

frailty and are associated with mortality in an HIV-positive population. We identified a

panel of 393 CpG sites that were highly predictive for participant with frailty. We also

found that ensemble predicted frailty was strongly associated with mortality in the HIV-

positive population in our cohort. In addition, these machine learning-selected 393

DNAm features lied in genes involved in HIV pathogenesis and progression. Thus, we

identified a panel of 393 DNAm biomarkers that add knowledge to the epigenetic

mechanisms underlying frailty and mortality among people living with HIV.

We demonstrated that machine learning approach is robust to identify biologically

relevant DNAm marks to predict frailty in HIV-positive individuals. One of the challenges

for machine learning method is overfitting model that leads to a bias of prediction. We

took the several steps to address potential overfitting in developing the ensemble

prediction models: 1) model development and final model selection were conducted

separately in training set and validation set; 2) 10-fold cross-validation was performed

during the training; 3) the use of ensemble model that aggregate prediction results from

multiple base models instead of arbitrary choice of a specific machine learning

prediction model; 4) the final model was evaluated in an independent test set. We

further observed that performance of different model generated by individual machine

learning method varied. Ensemble-based modeling method appears outperform than

individual modeling method and can adjust the imbalanced performance among

individual models. Our results suggested that ensemble-selected panel of CpG sites

was relatively stable and robust.

Our results show that the frailty predicted by the selected CpG biomarker is

strongly associated with mortality in a HIV-positive population. The finding is consistent

with previous literature showing that DNAm marks in blood predict mortality in a HIV-

negative population (39). Machine learning enables to select informative CpGs under

epigenome-wide significant threshold that have predictive values to a phenotype.

This panel of 393 CpG sites are biologically meaningful and may shed light on our

understanding of the biological mechanisms of frailty for HIV-positive individuals. We

found that 30 out of 393 CpGs reached epigenome-wide significance. The majority of

the 393 CpG sites are located within or near genes that are involved in known HIV

pathology and progression. For example, cg22930808 on *PARP9 and* cg07107453 on

IFI44L were selected by machine learning and also reached epigenome-wide

significance*,* which both genes are involved in *HIV pathogenesis.* cg12359279 is

located in the *MX1* gene (Interferon-Induced GTP-Binding Protein Mx1). *MX1* encodes

a GTP-metabolizing protein induced by interferon I and II and is involved in interferon

gamma signaling and Toll-like signaling pathway. The biological relevance of these 393

CpG sites was further supported by the gene ontology enrichment analysis. The top

enriched pathways such as response to virus and cytokine receptor binding may point

out important biological pathways that leads to frailty and increased risk of mortality

among people living with HIV.

We acknowledge several limitations in this study. The generalizability of the

selected CpG sites may be limited because our samples were predominantly middle-

aged men, which may not generalize to frailty in a different age group. All samples in

our study are HIV-positive and the identified CpGs have a limited application to HIV-

negative population as we discussed above. Future studies in diverse populations is

warranted to validate the selected methylation features.

Conclusions

We identified a panel of 393 predictive DNAm features in blood that was predictive of

frailty and mortality among people living with HIV. These DNAm features may serve as

biomarkers to identify frailty individuals and may help to prioritize genes to better

understand the mechanisms of frailty in HIV-positive population. These DNAm features

have potential for monitor HIV progression in future clinical care.

Figures

Figure 1: Flowchart of analytical procedures on selection of CpG sites in peripheral

blood methylome, machine learning prediction models to predict frailty, survival analysis,

gene ontology enrichment analysis, and epigenome-wide association analysis.

Figure 2: Variable Importance ranking of predictive machine learning CpG sites. Top 20

ranked CpG sites and 20 bootstraps are shown.

Figure 3: Area under the receiver operating characteristic(auROC) curve in the training set and validation set

Figure 4: Area under the precision-recall curve(auPRC) in the training set and validation set

Figure 5: Receiver operating characteristic(auROC) curve in the testing set

339
340

341 **Figure 6**: Kaplan-Meier curves of frailty and non-frailty groups

342
343

344 **Figure 7**: Top 8 enriched pathways by gene ontology term enrichment analysis of the

345 selected 393 CpG sites

346
347

348 **Tables**

Table 1: Study sample characteristics

	Training set (N=460)	Validation set (N=114)	Testing set (N=507)	p value*
Age (year, mean +/-sd)	52.56 (7.54)	51.21 (8.09)	50.86 (7.67)	0.002
Female (%)	6 (1.3)	1 (0.9)	11 (2.2)	0.452
Race (%)				
Caucasian	45 (9.8)	9 (7.9)	46 (9.1)	
African Americans	392 (85.2)	103 (90.4)	409 (80.7)	0.003
Other	23 (5.0)	2 (1.8)	52 (10.3)	
Smokers (%)	360 (59.4)	309 (58.4)	294 (58.0)	0.719
HIV treatment adherence (%)	362 (78.7)	85 (74.6)	382 (75.3)	0.399
CD4 count	432.68 (291.43)	411.82 (281.55)	450.61 (280.05)	0.287
log 10 HIV-1 viral load	2.76 (1.22)	2.68 (1.17)	2.83 (1.22)	0.399
High frailty (%)	162 (35.2)	40 (35.1)	131 (25.8)	0.004
10-year mortality (%)	123 (26.7)	32 (28.1)	121 (23.9)	0.477

*ANOVA test is used for continous variables, chi-square test is used for categorical variables

349
350

Table 2: Gene ontology term enrichment analysis of the selected 393 CpG sites that predict frailty in a HIV-positive population

Term	Total genes	Predictive Genes	P value
tumor necrosis factor receptor superfamily binding	46	7	8.33E-06
response to virus	303	15	4.26E-05
defense response	1505	39	1.29E-04
mitochondrial DNA metabolic process	18	4	1.43E-04
cytokine receptor binding	267	12	1.48E-04
regulation of response to interferon-gamma	25	4	4.15E-04
regulation of interferon-gamma-mediated signaling pathway	25	4	4.15E-04
cell-cell adhesion mediator activity	50	6	4.43E-04
intrinsic component of the cytoplasmic side of the plasma membrane	7	3	4.76E-04
immune response	1896	45	4.97E-04

Table 3: Overlapping CpG sites between machine learning selected CpG sites for frailty and epigenome-wide significant CpG sites on frailty

probe	Chr	Position	Nearest gene	Variable Importance	Meta Effect (SE)	Meta P	Refgene group	Relation to CpG island
cg01971407	11	313624	IFITM1	9.9	-0.0399 (0.0039)	8.05E-25	TSS1500	N_Shelf
cg22930808	3	122281881	PARP9;DTX3L	13.7	-0.1057 (0.0105)	7.24E-24	5UTR;TSS1500	N_Shore
cg23570810	11	315102	IFITM1	13.0	-0.0638 (0.0065)	1.15E-22	Body	N_Shore
cg14864167	8	66751182	PDE7A	12.0	-0.0832 (0.0085)	1.54E-22	Body	N_Shelf
cg01190666	20	62204908	PRIC285	19.4	-0.0343 (0.0035)	1.79E-22	5UTR	N_Shore
cg11702942	8	144102584	LY6E;LY6E	7.8	-0.0382 (0.004)	7.52E-22	Body;Body	S_Shore
cg03607951	1	79085586	IFI44L	23.0	-0.0683 (0.0072)	3.58E-21	TSS1500	
cg03848588	9	32525008	DDX58	14.4	-0.0274 (0.0029)	6.02E-21	Body	N_Shore
cg04582010	11	313120	IFITM1	22.1	-0.0455 (0.0052)	2.19E-18	TSS1500	S_Shore
cg18394552	5	159428643		24.4	0.0342 (0.0043)	1.57E-15		
cg03753191	13	43566902	EPSTI1;EPSTI1	4.1	-0.018 (0.0023)	2.43E-15	TSS1500	S_Shore
cg17267239	1	173640200	ANKRD45	21.8	-0.0186 (0.0025)	1.22E-13	TSS1500	S_Shore
cg12461141	11	5710654	TRIM22	37.6	-0.0274 (0.0037)	1.37E-13	TSS1500	
cg09251764	17	6659070	XAF1;XAF1	13.8	-0.0142 (0.002)	3.93E-13	TSS200	
cg05626226	4	106515450	FLJ20184	11.5	0.0279 (0.004)	2.45E-12	Body	
cg22959742	10	13913931	FRMD4A	16.4	0.0289 (0.0041)	3.08E-12	Body	
cg16936953	17	57915665	TMEM49	11.3	-0.0379 (0.0056)	1.95E-11	Body	
cg18181703	17	76354621	SOCS3	32.6	-0.0215 (0.0033)	1.15E-10	Body	N_Shore
cg07107453	1	79114976	IFI44	4.8	-0.0292 (0.0046)	2.26E-10	TSS1500	
cg25114611	6	35696870	FKBP5;LOC285847	12.8	-0.0125 (0.002)	4.78E-10	TSS1500;Body	S_Shore
cg01059398	3	172235808	TNFSF10	26.7	-0.0289 (0.0047)	7.85E-10	Body	
cg19459791	15	65363022		15.1	0.0159 (0.0026)	1.20E-09		S_Shelf
cg26282236	12	1025755	RAD52	30.2	0.0243 (0.0041)	3.63E-09	Body	

cg06357748	12	1025529	*RAD52*	10.7	0.0277 (0.0047)	4.12E-09	Body	
cg04442417	20	62191507	*PRIC285;PRIC285*	26.6	0.0201 (0.0035)	1.22E-08	Body	Island
cg14602222	12	1025663	*RAD52*	13.2	0.0241 (0.0042)	1.42E-08	Body	
cg26724018	11	5716255	*TRIM22*	11.9	-0.0171 (0.003)	1.49E-08	5UTR	
cg03084350	3	38065265	*PLCD1;PLCD1;PLCD1*	18.0	0.0114 (0.002)	2.05E-08	Body	N_Shore
cg00569896	4	204382		0.2	0.0254 (0.0047)	5.78E-08		N_Shore
cg12126344	1	12207564		8.4	-0.011 (0.002)	7.36E-08		

352
353

354
Legends

Figure 1: Flowchart of analytical procedures on selection of CpG sites in peripheral

blood methylome, machine learning prediction models to predict frailty, survival analysis,

gene ontology enrichment analysis, and epigenome-wide association analysis.

Figure 2: Variable Importance ranking of predictive machine learning CpG sites

Figure 3: Area under the receiver operating characteristic(auROC) curve in the training

set and validation set

Figure 4: Area under the precision-recall curve(auPRC) in the training set and

validation set

Figure 5: Receiver operating characteristic(auROC) curve in the testing set

Figure 6: Kaplan-Meier curves of frailty and non-frailty groups

Figure 7: Top 8 enriched pathways by gene ontology term enrichment analysis of the

selected 393 CpG sites

Figure 8: Epigenome-wide association (EWA) on frailty: quantile-quantile plot,

Manhattan plot and overlapping CpG sites between EWA significant CpGs and

predictive CpGs.

Figure S1: Distribution of Veteran Aging Cohort Study index (VACS index) between

training set and testing set

Table 1: Study sample characteristics

Table 2: Gene ontology term enrichment analysis of the selected 393 CpG sites that

predict frailty

Table 3: Overlapping CpG sites between machine learning selected CpG sites for frailty

and epigenome-wide significant CpG sites on frailty.

Table S1: Predictive CpG sites by variance importance

Table S2: Epigenome-wide significant CpG sites in meta-analysis of EWAS on frailty

List of abbreviations

AUC: Area Under Curve

CI: Confidence interval

DMR: differentially methylated region

DNA: Deoxyribonucleic acid

DNAm: DNA methylation

DAVID: Database for Annotation, Visualization and Integrated Discovery

EWA: epigenome-wide association

FDR: False discovery rate

FWER: Family-wise error rate

GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models

GO: Gene ontology

HIV: Human immunodeficiency virus

HM450K: Human Methylation 450K BeadChip

NK: Natural killer

PC: Principal component

QC: Quality control

SVM: Support Vector Machines

VACS: Veterans Aging Cohort Study

VACS index: Veterans Aging Cohort Study index

XGBoost: Extreme Gradient Boosting Tree

Declarations

Ethics approval and consent to participate

The study was approved by the committee of the Human Research Subject Protection

at Yale University and the Institutional Research Board Committee of the Connecticut

Veteran Healthcare System. All subjects provided written consents.

Availability of data and materials

Demographic and clinical variables and DNAm data for the VACS samples were

submitted to GEO dataset (GSE117861) and are available to the public. All codes for

analysis are also available upon a request to the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

The project was supported by the National Institute on Drug Abuse (R03DA039745,

R01DA038632, R01DA047063, R01DA047820).

Authors' contributions

CS was responsible for data analysis and manuscript preparation. ACJ provided DNA

samples, clinical data, and contributed to manuscript preparation. XZ was responsible

for the bioinformatics data processing. VM involved clinical data collection and

manuscript preparation. DH and EJ contributed to analytical approach and the

manuscript preparation. KX was responsible for the study design, study protocol,

sample preparation, data analysis, interpretation of findings, and manuscript preparation.

Acknowledgements

References

References

1.   Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV
infection is independently associated with frailty in middle-aged HIV type 1-infected individuals
compared with similar but uninfected controls. AIDS. 2016;30(2):241-50.
2.   Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: A
review. Eur J Intern Med. 2016;31:3-10.
3.   Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based
biomarkers in colorectal cancer: a systematic review. Biochimica et Biophysica Acta (BBA)-
Reviews on Cancer. 2016;1866(1):106-20.
4.   Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of
schizophrenia and bipolar disorder: a systematic review. BMC genetics. 2016;17(1):27.
5.   Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: A systematic
review on DNA methylation mechanisms. Journal of Psychosomatic Research. 2017;92:34-44.
6.   Li M, D'Arcy C, Li X, Zhang T, Joober R, Meng X. What do DNA methylation studies tell us
about depression? A systematic review. Translational psychiatry. 2019;9(1):68.
7.   Horvath S. DNA methylation age of human tissues and cell types. Genome biology.
2013;14(10):3156.
8.   Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
ageing. Nature Reviews Genetics. 2018:1.
9.   Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide
methylation profiles reveal quantitative views of human aging rates. Molecular cell.
2013;49(2):359-67.
10.   Liu C, Marioni RE, Hedman ÅK, Pfeiffer L, Tsai P-C, Reynolds LM, et al. A DNA
methylation biomarker of alcohol consumption. Molecular psychiatry. 2018;23(2):422.
11.   Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related
differential DNA methylation: 27K discovery and replication. The American Journal of Human
Genetics. 2011;88(4):450-7.
12.   Gao X, Zhang Y, Breitling LP, Brenner H. Relationship of tobacco smoking and smoking-
related DNA methylation with epigenetic age acceleration. Oncotarget. 2016;7(30):46878-89.
13.   Joubert BR, Håberg SE, Nilsen RM, Wang X, Vollset SE, Murphy SK, et al. 450K
epigenome-wide scan identifies differential DNA methylation in newborns related to maternal
smoking during pregnancy. Environmental health perspectives. 2012;120(10):1425-31.
14.   Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Frontiers in genetics.
2013;4:132.
15.   Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, et al. Machine learning
selected smoking-associated DNA methylation signatures that predict HIV prognosis and
mortality. 2018;10(1):155.
16.   Zhang R, Miao Q, Wang C, Zhao R, Li W, Haile CN, et al. Genome-wide DNA methylation
analysis in alcohol dependence. Addiction biology. 2013;18(2):392-403.
17.   Kraiczy J, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, et al. DNA methylation
defines regional identity of human intestinal epithelial organoids and undergoes dynamic
changes during development. Gut. 2019;68(1):49-61.

18.   Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-Wide
Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic
Steatosis. Gastroenterology. 2017;153(4):1096-106.e2.
19.   Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and cancer diagnosis.
International journal of molecular sciences. 2013;14(7):15029-58.
20.   Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA
methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer
cell. 2010;17(1):13-27.
21.   Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al. Molecular
subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast
cancer research. 2010;12(3):R36.
22.   Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nature
Reviews Genetics. 2019;20(2):109-27.
23.   Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer
therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403-18.
24.   Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella Jr FJ, et al.
Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-
related phenotype of men with or at risk for HIV infection. The Journal of infectious diseases.
2016;215(2):228-37.
25.   Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, et al. Epigenome-wide differential
DNA methylation between HIV-infected and uninfected individuals. Epigenetics.
2016;11(10):750-60.
26.   Chen J, Huang Y, Hui Q, Mathur R, Gwinn M, So-Armah K, et al. Epigenetic Associations
with Estimated Glomerular Filtration Rate (eGFR) among Men with HIV Infection. Clin Infect Dis.
2019.
27.   Mathur R, Hui Q, Huang Y, Gwinn M, So-Armah K, Freiberg MS, et al. DNA Methylation
Markers of Type 2 Diabetes Mellitus Among Male Veterans With or Without Human
Immunodeficiency Virus Infection. J Infect Dis. 2019;219(12):1959-62.
28.   Breitling LP, Saum K-U, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated
with the epigenetic clock but not with telomere length in a German cohort. Clinical Epigenetics.
2016;8(1):21.
29.   Sanchez-Conde M, Rodriguez-Centeno J, Dronda F, Lopez JC, Jimenez Z, Berenguer J, et
al. Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.
Epigenomics. 2019;11(5):501-9.
30.   Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock.
The Journal of infectious diseases. 2015;212(10):1563-73.
31.   Rickabaugh TM, Baxter RM, Sehl M, Sinsheimer JS, Hultin PM, Hultin LE, et al.
Acceleration of age-associated methylation patterns in HIV-1-infected adults. PloS one.
2015;10(3):e0119201.
32.   Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al.
Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age
and epigenetic targeting of HLA. Molecular cell. 2016;62(2):157-68.

33.   Nelson KN, Hui Q, Rimland D, Xu K, Freiberg MS, Justice AC, et al. Identification of HIV
infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive,
treatment-naive U.S. veterans. AIDS. 2017;31(4):571-5.
34.   Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, et al. DNA methylation age
of blood predicts all-cause mortality in later life. Genome biology. 2015;16(1):25.
35.   Marioni RE, Harris SE, Shah S, McRae AF, von Zglinicki T, Martin-Ruiz C, et al. The
epigenetic clock and telomere length are independently associated with chronological age and
mortality. International journal of epidemiology. 2016;45(2):424-32.
36.   Perna L, Zhang Y, Mons U, Holleczek B, Saum K-U, Brenner H. Epigenetic age
acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort.
Clinical epigenetics. 2016;8(1):64.
37.   Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, et al. DNA methylation
age is associated with mortality in a longitudinal Danish twin study. Aging Cell. 2016;15(1):149-
54.
38.   Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a
predictor of disease and mortality risk: a systematic review and meta-analysis. Clin Epigenetics.
2019;11(1):62.
39.   Zhang Y, Wilson R, Heiss J, Breitling LP, Saum K-U, Schöttker B, et al. DNA methylation
signatures in peripheral blood strongly predict all-cause mortality. Nature communications.
2017;8:14617.
40.   Holder LB, Haque MM, Skinner MK. Machine learning for epigenetics and future medical
applications. Epigenetics. 2017;12(7):505-14.
41.   Crowgey EL, Marsh AG, Robinson KG, Yeager SK, Akins RE. Epigenetic machine learning:
utilizing DNA methylation patterns to predict spastic cerebral palsy. BMC Bioinformatics.
2018;19(1):225.
42.   Dietterich TG, editor Ensemble methods in machine learning. International workshop on
multiple classifier systems; 2000: Springer.
43.   Dietterich TG. Ensemble learning. The handbook of brain theory and neural networks.
2002;2:110-25.
44.   Moon H, Ahn H, Kodell RL, Baek S, Lin C-J, Chen JJ. Ensemble methods for classification
of patients for personalized medicine with high-dimensional data. Artificial Intelligence in
Medicine. 2007;41(3):197-207.
45.   Alghamdi M, Al-Mallah M, Keteyian S, Brawner C, Ehrman J, Sakr S. Predicting diabetes
mellitus using SMOTE and ensemble machine learning approach: The Henry Ford ExercIse
Testing (FIT) project. PloS one. 2017;12(7).
46.   Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans
aging cohort study (VACS): overview and description. 2006;44(8 Suppl 2):S13.
47.   Justice AC, Modur S, Tate JP, Althoff KN, Jacobson LP, Gebo K, et al. Predictive accuracy
of the Veterans Aging Cohort Study (VACS) index for mortality with HIV infection: a north
American cross cohort analysis. Journal of acquired immune deficiency syndromes (1999).
2013;62(2):149.
48.   Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally
generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (London,
England). 2013;27(4):563-72.

49. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, et al. Predictive
accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North
American cross cohort analysis. Journal of acquired immune deficiency syndromes (1999).
2013;62(2):149-63.
50. Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan S-T, et al. A coherent approach for
analysis of the Illumina HumanMethylation450 BeadChip improves data quality and
performance in epigenome-wide association studies. 2015;16(1):37.
51. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi:
a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA
methylation microarrays. 2014;30(10):1363-9.
52. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al.
DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics.
2012;13(1):86.
53. Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of statistical learning: data
mining, inference and prediction. The Mathematical Intelligencer. 2005;27(2):83-5.
54. Kotsiantis SB, Zaharakis I, Pintelas P. Supervised machine learning: A review of
classification techniques. Emerging artificial intelligence applications in computer engineering.
2007;160:3-24.
55. Chen T, Guestrin C, editors. Xgboost: A scalable tree boosting system. Proceedings of the
22nd acm sigkdd international conference on knowledge discovery and data mining; 2016: ACM.
56. Ogutu JO, Piepho H-P, Schulz-Streeck T. A comparison of random forests, boosting and
support vector machines for genomic selection. BMC Proc. 2011;5 Suppl 3(Suppl 3):S11-S.
57. Kuhn MJJoss. Building predictive models in R using the caret package. 2008;28(5):1-26.
58. Brodersen KH, Ong CS, Stephan KE, Buhmann JM, editors. The balanced accuracy and its
posterior distribution. 2010 20th International Conference on Pattern Recognition; 2010: IEEE.
59. Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from
Illumina's HumanMethylation450 platform. Bioinformatics. 2015;32(2):286-8.
60. Geeleher P, Hartnett L, Egan LJ, Golden A, Raja Ali RA, Seoighe C. Gene-set analysis is
severely biased when applied to genome-wide methylation data. Bioinformatics.
2013;29(15):1851-7.
61. Willer CJ, Li Y, Abecasis GRJB. METAL: fast and efficient meta-analysis of genomewide
association scans. 2010;26(17):2190-1.
591

Figure S1